CRATER tumor niches facilitate CD8<sup>+</sup> T cell engagement and correspond with immunotherapy success.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41109214.
- Also identified by DOI 10.1016/j.cell.2025.09.021 and PMC identifier 12604482.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
T cell-mediated tumor killing underlies immunotherapy success. Here, we used long-term in vivo imaging and high-resolution spatial transcriptomics of zebrafish endogenous melanoma, as well as multiplex imaging of human melanoma, to identify domains facilitating the immune response during immunotherapy. We identified cancer regions of antigen presentation and T cell engagement and retention (CRATERs) as pockets at the stroma-melanocyte boundaries of zebrafish and human melanoma. CRATERs are rich in antigen-recognition molecules, harboring the highest density of CD8<sup>+</sup> T cells in tumors. In zebrafish, CD8<sup>+</sup> T cells formed prolonged interactions with melanoma cells within CRATERs, characteristic of antigen recognition. Following immunostimulatory treatment, CRATERs expanded, becoming the major sites of activated CD8<sup>+</sup> T cell accumulation and tumor killing. In humans, elevation in CRATER density in biopsies following immune checkpoint blockade (ICB) therapy correlated with a clinical response to therapy. CRATERs are structures that show active tumor killing and may be useful as a diagnostic indicator for immunotherapy success.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Immunotherapy
- Melanoma
- Tumor Microenvironment